 NEW YORK , June 8, 2022 PRNewswire -- Immunic , Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, industry and investor conferences in June: June 10-13: 13th International Congress on Autoimmunity. Evelyn Peelen, Ph.D. 